

Omega Pharma sells production unit in Marseille to Fareva Group

Nazareth (Belgium), 9 October 2009 (5:45 PM CET) – Omega Pharma, the specialist in the development and commercialization of over-the-counter medicines and health products, has sold its production site in Marseille to Fareva, a European specialist in the manufacturing of cosmetics and pharmaceuticals.

The pharmaceutical plant in Marseille provides employment to 45 persons, and is specialized in a.o. aerosol products.

Fareva is one of the largest and fastest growing third-party manufacturers for the OTC sector in Europe, with an annual turnover exceeding 700 million euro and over 5,000 employees. Fareva operates already 25 plants - in its French home market, Belgium, Germany, the UK, Italy, Switzerland, Russia, Ukraine and Turkey - and has the know-how and customer base which enable a considerable enhancement of the efficiency at the Marseille plant.

Omega Pharma and Fareva have also concluded a long-term partnership, specifying that Fareva will manufacture and/or develop a number of products for Omega Pharma.

Bernard Fraisse, CEO of Fareva: “I am pleased with the expansion of the Fareva Group at Marseille as well as with the partnership with Omega Pharma. Our specialized manufacturing units, our extended efficiency and our structural customer base have made Fareva a trendsetting company in its sector, in Europe. This agreement is perfectly aligned with our vision for the future. It will enable Omega Pharma and Fareva - each in its area - to further improve their focus and thus enhance their growth potential.”

Marc Coucke, CEO of Omega Pharma: “Optimization of our product sourcing is one of our top priorities. Efficiency and flexibility are essential factors in this respect. Omega Pharma is increasingly using centralized sourcing structures, in which a few own plants are involved, along with our joint-venture in India and a limited number of external partners. I look forward

to the cooperation with Fareva, which will be an excellent partner, thanks to its growing efficiency and its strong degree of specialization.”

Omega Pharma sells the Marseille plant in an asset deal, worth about twice the (limited) book value. While the deal implies a reduction of the group’s turnover of about 5 million euro on an annual basis (i.e. the turnover from current manufacturing operations on behalf of external customers) as of 4Q2009, it also leads to more efficient sourcing operations, which will positively impact the group’s profitability.

Financial calendar

Thursday 15 October 2009 (5:45 PM CET) Trading Update on the third quarter 2009

Thursday 21 January 2010 (5:45 PM CET) Trading Update on the fourth quarter 2009

For more information, please contact

Chris Van Raemdonck, Investor Relations

Chris.Vanraemdonck@omega-pharma.be

Tel: 0032/9/381.03.31

Mobile: 0032/499/58.55.31

www.omega-pharma.be

www.fareva.com